XTalks

MARCH 28, 2024

For CRC, treatment options that are targeting genetic mutations such as BRAF , KRAS and HER2 have been developed. Furthermore, the introduction of multi-targeted kinase inhibitors and monoclonal antibodies is also being examined as a possible form of therapy. Yang Liu and CFO Abid Ansari – Xtalks Life Science Podcast Ep.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

pharmaphorum

FEBRUARY 17, 2022

SCD is one of the most prevalent genetic diseases in Europe, affecting approximately 52,000 people, and is more common in those whose ancestors are from sub-Saharan Africa, although it is also seen in people of Hispanic, South Asian, Southern European and Middle Eastern ancestry.

Drugs 59

Drugs Gene Therapy Gene Editing Gene 59

Cloudbyz

MARCH 6, 2024

For example, monoclonal antibodies, a type of biologic, can selectively bind to specific targets such as proteins or cells involved in disease processes, thereby modulating immune responses or inhibiting disease progression. One of the key features of biologics is their ability to mimic or augment natural biological processes within the body.

Gene 75

Gene Immune Response Manufacturing Gene Therapy 75

XTalks

NOVEMBER 30, 2023

More Investigational Therapies for HIV Are on the Way American Gene Technologies, a pioneering biotech company headquartered in Rockville, Maryland, has released promising results from its Phase I trial of AGT103-T, a gene therapy designed for individuals with chronic HIV disease. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

NOVEMBER 3, 2020

Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, announced today the U.S. LogicBio Therapeutics is dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms. LEXINGTON, Mass., About LogicBio Therapeutics.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 76

Drugs Life Science Gene Therapy Genome 76

pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed.

Antibody 52

Antibody Immune Response Production Engineer 52

Worldwide Clinical Trials

MAY 30, 2024

Biotech Solutions: The Emergence of Various Cell, Gene, & Immunotherapy Options in ALS One up-and-coming area of research is gene therapy, which broadly encompasses any therapeutics that add or edit genetic material.

Gene 204

Gene Clinical Trials Clinical Trials Gene Therapy 204

XTalks

JANUARY 4, 2024

The adeno-associated viral (AAV) vector-based gene therapy received approval in Canada for the treatment of adults aged 18 years or older with moderately-severe to severe hemophilia B who are negative for neutralizing antibodies to variant AAV serotype Rh74, Pfizer Canada revealed in its announcement of the approval.

Gene Therapy 111

Gene Therapy Gene Gene Editing Sales 111

Drug Discovery World

JULY 18, 2023

Incorporating in vivo pooled CRISPR screens has allowed for the interrogation of thousands of genetic perturbations in cells, leading to the determination of the involvement of molecules (PTPN2, ADAR1, or DHX37) in immune checkpoint inhibitor (ICI) responsiveness and T cell activation.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

SEPTEMBER 28, 2022

Satchi-Fainaro and her team tried to inhibit the expression of the protein and its receptors in genetically engineered lab models and in 3D models of primary melanoma and brain metastases.

Research 52

Research Gene Editing Genetic Engineering Protein 52

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. One of the most exciting recent developments is the use of gene editing tools to create cell and gene therapies.

Research 52

Research Drugs Protein RNA 52

Pharma Marketing Network

JANUARY 20, 2021

In other areas of the industry (such as cell and genetic medicine development) progress continued at an impressively brisk pace despite the pandemic. When the patient is referred, a large historical data set (including biomarker and genetic data) will be available to the provider.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

XTalks

DECEMBER 24, 2020

From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. Antibody drugs were also developed as targeted COVID-19 treatments.

Life Science 111

Life Science Vaccination Vaccine Gene 111

Pharmaceutical Technology

MARCH 2, 2023

ImmunoGen has announced an agreement granting rights to Vertex Pharmaceuticals to carry out research using antibody-drug conjugate (ADC) technology for the discovery of new targeted conditioning agents. The research using ImmunoGen’s technology will enable the discovery of the agents for use with gene editing.

Gene Editing 130

Gene Editing Gene Development Research 130